Brisdelli F, D\'Andrea Gabriele, Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties[J]. Curr Drug Metab, 2009,10(6):530.
[2]
Xu Q, Si L Y. Resveratrol role in cardiovascular and metabolic health and potential mechanisms of action[J]. Nutr Res,2012,32(9):648.
[3]
Chu L M, Lassaletta A D, Robich M P, et al. Resveratrol in the prevention and treatment of coronary artery disease[J]. Curr Atheroscler Rep,2011,13(6):439.
[4]
Olavi Pelkonen, Miia Turpeinen, Jukka Hakkola, et al. Inhibition and induction of human cytochrome P450 enzymes: current status[J]. Arch Toxicol,2008, 82(10): 667.
[5]
Ulrich M Zanger, Miia Turpeinen, Kathrin Klein. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation[J]. Anal Bioanal Chem,2008, 369(6):1093.
[6]
Vastano B C, Chen Y, Zhu N, et al. Isolation and identification of stilbenes in two varieties of polygonum cuspidatum[J]. J Agric Food Chem,2000,48(2):253.
[7]
Joseph A B, David A S. Therapeutic potential of resveratrol: the in vivo evidence[J].Nature Review, 2006,6(5):493.
[8]
Wu J M,Hsieh T C. Resveratrol: a cardioprotective substance[J]. Ann N Y Acad Sci,2011,1215:16.
[9]
Guengerich F P. Reactions and significance of cytochrome P-450 enzymes[J]. J Biol Chem,1991,266(16):10019.
William K Chan, Anthony B, Delucchi. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4[J]. Life Sci, 2000,67(25): 3103.
[15]
Thomas K H, Yeung Rosita K Y. Effect of trans-resveratrol on 7-benzyloxy -4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5[J]. Can J Physiol Pharmacol, 2001,79(3): 220.
[16]
Bertrand Piver, Franc ois Berthou, Yvonne Dreano. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components[J]. Toxicol Lett,2001,125(1/3): 83.
[17]
Yu C, Shin Y G, Kosmeder J W, et al. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate[J]. Rapid Commun Mass Spectrom, 2003(17): 307.
[18]
Detampel P, Beck M, Krhenbühl S, et al.Drug interaction potential of resveratrol[J].Drug Metab Rev,2012,44(3):253.
[19]
James M Smoliga, Joseph A Baur, Heather A Hausenblas. Resveratrol and health——A comprehensive review of human clinical trials[J].Mol Nutri Food Res,2011,8(55):1129.
[20]
Chu V, Einolf H J, Evers R,et al. In vitro and in vivo induction of cytochrome P450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective[J]. Drug Metab Dispos,2009,37(7):1339.
Ondej Zendulka, Lucia Zzhradní ková , Jan Juica. The influence of trans-resveratrol and quercetin on the activity of CYP1A2 in rat[J]. Czech Jof Food Sci, 2008,26:S60.
[23]
Zendulka O, Totusek J, Sulcova A. Intersexual differences in inhibitory influence of trans-resveratrol on activity of cytochrome P450 2D2 in rats[J]. Neuro Endocrinol Lett, 2009,30(1):88.
[24]
Hebbar V, Shen G, Hu R, et al. Toxicogenomics of resveratrol in rat liver[J].Life Sci,2005,76(20):2299.
[25]
Soon-Pyo Hong, Dong-Hyun, Choi Jun-Shik Choi. Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats[J]. Cardiovasc Ther, 2008,26(4):269.
[26]
Stewart N A, Buch S C, Conrads T P, et al. A UPLC-MS/MS assay of the "Pittsburgh cocktail": six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilution[J].Analyst,2011,136(3):605.
[27]
H-H Sherry Chow, Linda L G, Chiu-Hsieh H, et al. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study[J]. Cancer Prev Res, 2010,3(9):1168.
[28]
Allan Lancon, Jacques Kaminski, Esmerina Tili,et al.Control of microRNA expression as a new way for resveratrol to deliver its beneficial effects[J]. J Agric Food Chem, 2012,60(36): 8783.
[29]
Thomas K H C, Wendy B K L, Hin H K. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogenactivating human cytochrome P450 1B1[J]. Can J Physiol Pharmacol,2000,78(11): 874.
[30]
Einem L T, Poirier M C, Divi R L.The resveratrol analogue, 2,3\',4,5\'-tetramethoxystilbene, does not inhibit CYP gene expression, enzyme activity and benzo pyrene-DNA adduct formation in MCF-7 cells exposed to benzo pyrene[J]. Mutagenesis, 2011, 26(5):629.
